


ML-792

Cat. No.:	HY-108702		
CAS No.:	1644342-14-2		
Molecular Formula:	C ₂₁ H ₂₃ BrN ₆ O ₃ S		
Molecular Weight:	551.41		
Target:	E1/E2/E3 Enzyme		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (181.35 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		1.8135 mL	9.0677 mL	18.1353 mL
		5 mM		0.3627 mL	1.8135 mL	3.6271 mL
10 mM			0.1814 mL	0.9068 mL	1.8135 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.77 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (3.77 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.77 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	ML-792 is a potent and selective inhibitor of SAE/SUMO1 and SAE/SUMO2 in enzymatic assays (IC ₅₀ values of 3 and 11 nM, respectively) compared with NAE/NEDD8 and UAE/ubiquitin (IC ₅₀ > values of 32 μM and >100 μM, respectively) ^[1] .
IC₅₀ & Target	IC ₅₀ : 3 nM (SAE/SUMO1), 11 nM (SAE/SUMO2) ^[1]
In Vitro	ML-792 (0.0007-5 μM; 4 hours) inhibits SAE and SUMO-pathway activities in HCT116 cells ^[1] . ML-792 (0.001-10 μM; 72 hours) inhibits cell proliferation and decreases cancer cell viability in MDA-MB-468, MDA-MB-231,

HCT116, Colo-205, and A375^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	Human breast cancer cells MDA-MB-468 and MDA-MB-231; human colon carcinoma cells HCT116 and Colo-205; human melanoma cell line A375
Concentration:	0.001, 0.01, 0.1, 1, 10 μ M
Incubation Time:	72 hours
Result:	Demonstrated a dose-dependent viability effect with EC ₅₀ values of 0.06 μ M in MDA-MB-468 cells to 0.45 μ M in A375 cells.

Western Blot Analysis^[1]

Cell Line:	HCT116 cells
Concentration:	0, 0.0007, 0.002, 0.007, 0.02, 0.06, 0.19, 0.56, 1.7, 5 μ M
Incubation Time:	4 hours
Result:	Revealed a dose-dependent decrease in the SAE and UBC9 thioester levels.

CUSTOMER VALIDATION

- Nat Commun. 2022 Nov 11;13(1):6840.
- Nat Commun. 2022 Sep 29;13(1):5726.
- Nat Commun. 2022 Sep 3;13(1):5204.
- Mol Cell. 2023 Jan 14;S1097-2765(23)00003-5.
- Mol Cell. 2020 Jul 2;79(1):54-67.e7.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. He X, et al. Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. Nat Chem Biol. 2017 Nov;13(11):1164-1171.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA